The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.

Inclusion Criteria:

• Chinese ethnicity;
• History of allergic conjunctivitis within the last 2 years;
• Positive skin prick test or skin intradermal test documented by a lab report within 24 months of, or at the baseline visit;
• Clinical diagnosis of allergic conjunctivitis with specific signs and symptoms;
• Understand and sign an informed consent form;
• Willing and able to make required study visits and follow study instructions, and comply with dosing study medication as instructed;
• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Contraindications or hypersensitivity to study medications or their components;
• Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal) in either eye;
• Any ocular condition that could affect the study outcomes;
• Presumed or actual ocular infection or history of ocular herpes in either eye;
• Known history of retinal detachment, diabetic retinopathy, or any progressive retinal disease;
• Willing and able to avoid the use of any other topical ocular medication(s) (including artificial tear products);
• Any significant illness that could be expected to interfere with the study, particularly any autoimmune disease;
• Intraocular surgery in either eye within 6 months, or ocular laser surgery in either eye within 3 months, or anticipation of ocular surgery during the study; ocular trauma in either eye within 3 months of baseline visit;
• Clinically relevant recent (within 6 months of baseline visit) history of or current severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, autoimmune disease and other relevant systemic diseases that would preclude the safe administration of a topical antihistamine/mast cell stabilizer in the opinion of the Investigator;
• Use of systemic medication(s) on a chronic dosing regimen for less than 1 month or have changed dosage within the month prior to baseline visit;
• Use of any disallowed medication (topical, topical ophthalmic, systemic and/or injectable) during the period indicated prior to baseline visit. These medications are also not allowed during the study. Disallowed medications include all anti-allergy therapies including those contained in prescription or over-the-counter sleeping aids;
• Use of cold compresses on the eyes during the course of the study;
• Cannot be dosed in both eyes;
• Cannot avoid contact lens wear during the course of the study;
• Therapy with another investigational agent within 30 days of baseline visit, or during the study;
• Women of childbearing potential who are pregnant, intend to become pregnant during the study period, breast-feeding, or not using adequate birth control methods;
• Other protocol-specified exclusion criteria may apply.

This analysis population includes all participants who were randomized, received drug, had at least one on-therapy visit, satisfied inclusion/exclusion criteria, and had no major protocol deviations (Per Protocol Set).

Adverse events (AEs) were collected from the time of informed consent and for the duration of participation in the study (2 weeks). This analysis group includes all participants who received study treatment. Ocular adverse events are presented for both study eye and non-study eye combined. AEs are reported as pre-treatment and treatment-emergent.

An AE is defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. Reports of AEs were obtained through solicited and spontaneous comments from the participants.